Pasar al contenido principal

DESENCADENANTE INFECCIOSO EN LA PB-ALL INFANTIL - DESCIFRANDO LOS MECANISMOS RESPONSABLES DE LA EVOLUCION CLONAL CON EL OBJETIVO DE PREVENIR LA LEUCEMIA

RTI2018-093314-B-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2018
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 18
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Infectious stimuli promote malignant B-cell acute lymphoblastic leukemia in the absence of AID

  • Rodríguez-Hernández, Guillermo
  • Opitz, Friederike V.
  • Delgado, Pilar
  • Walter, Carolin
  • Álvarez-Prado, Angel Francisco
  • González-Herrero, Inés
  • Auer, Franziska
  • Fischer, Ute
  • Janssen, Stefan
  • Bartenhagen, Christoph
  • Raboso-Gallego, Javier
  • Casado-García, Ana
  • Orfao, Alberto
  • Blanco, Óscar
  • Alonso-López, D.
  • Rivas, Javier de las
  • González de Tena-Dávila, Sara
  • Müschen, Markus
  • Dugas, Martin
  • García-Criado, Francisco Javier
  • García-Cenador, Begoña
  • Vicente-Dueñas, Carolina
  • Hauer, Julia
  • Ramiro, Almudena R.
  • Sánchez García, Isidro
  • Borkhardt, Arndt
The prerequisite to prevent childhood B-cell acute lymphoblastic leukemia (B-ALL) is to decipher its etiology. The current model suggests that infection triggers B-ALL development through induction of activation-induced cytidine deaminase (AID; also known as AICDA) in precursor B-cells. This evidence has been largely acquired through the use of ex vivo functional studies. However, whether this mechanism governs native non-transplant B-ALL development is unknown. Here we show that, surprisingly, AID genetic deletion does not affect B-ALL development in Pax5-haploinsufficient mice prone to B-ALL upon natural infection exposure. We next test the effect of premature AID expression from earliest pro-B-cell stages in B-cell transformation. The generation of AID off-target mutagenic activity in precursor B-cells does not promote B-ALL. Likewise, known drivers of human B-ALL are not preferentially targeted by AID. Overall these results suggest that infections promote B-ALL through AID-independent mechanisms, providing evidence for a new model of childhood B-ALL development., Research in CVD group is partially supported by FEDER, “Miguel Servet” Grant (CP14/00082 - AES 2013–2016) from the Instituto de Salud Carlos III (Ministerio de Economía y Competitividad), “Fondo de Investigaciones Sanitarias/Instituto de Salud Carlos III” (PI17/00167). J.H. has been supported by ERAPer Med, the German Cancer AID (Translational Oncology Program 70112951), the DKTK German Cancer Consortium Joint funding program “Targeting MYC” L*10, The German Jose Carreras Foundation (DJCLS 02R/2016), and the Kinderkrebsstiftung (2016/17). A.R.R. was supported by ERC StG BCLYM-207844, SAF2013-42767-R and SAF2016-75511-R grants and co-funding by Fondo Europeo de Desarrollo Regional (FEDER). P.D. was funded by the Asociación Española Contra el Cancer. The CNIC is supported by the Ministerio de Ciencia, Innovación y Universidades (MCNU) and the Pro CNIC Foundation, and is a Severo Ochoa Center of Excellence (SEV-2015-0505). A.B. has been supported by the German Children’s Cancer Foundation and the Federal Ministry of Education and Research, Bonn, Germany. Research in ISG group is partially supported by FEDER and by SAF2015-64420-R MINECO/FEDER, UE, RTI2018-093314-B-I00 MCIU/AEI/FEDER, UE, by Junta de Castilla y León (UIC-017, CSI001U16, and CSI234P18). I.S.G. lab is a member of the EuroSyStem and the DECIDE Network funded by the European Union under the FP7 program. A.B. and I.S.G. have been supported by the German Carreras Foundation (DJCLS R13/26) and by the German Federal Office for Radiation Protection (BfS)-Germany (FKZ: 3618S32274). G.R.H., A.C.-G and S.G.T.D. were supported by FSE-Conserjería de Educación de la Junta de Castilla y León (CSI001-15, CSI067-18 and CSI003-17, respectively). F.A. was supported by a Deutsche Forschungsgemeinschaft (DFG) fellowship (AU 525/1-1)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Are leukaemic stem cells restricted to a single cell lineage?

  • Brown, Geoffrey
  • Sánchez, Lucía
  • Sánchez García, Isidro
This article belongs to the Collection Feature Papers in Molecular Biology., Cancer-stem-cell theory states that most, if not all, cancers arise from a stem/uncommitted cell. This theory revolutionised our view to reflect that cancer consists of a hierarchy of cells that mimic normal cell development. Elegant studies of twins who both developed acute lymphoblastic leukaemia in childhood revealed that at least two genomic insults are required for cancer to develop. These ‘hits’ do not appear to confer a growth advantage to cancer cells, nor do cancer cells appear to be better equipped to survive than normal cells. Cancer cells created by investigators by introducing specific genomic insults generally belong to one cell lineage. For example, transgenic mice in which the LIM-only 2 (LMO2, associated with human acute T-lymphoblastic leukaemia) and BCR-ABLp210 (associated with human chronic myeloid leukaemia) oncogenes were active solely within the haematopoietic stem-cell compartment developed T-lymphocyte and neutrophil lineage-restricted leukaemia, respectively. This recapitulated the human form of these diseases. This ‘hardwiring’ of lineage affiliation, either throughout leukaemic stem cell development or at a particular stage, is different to the behaviour of normal haematopoietic stem cells. While normal cells directly commit to a developmental pathway, they also remain versatile and can develop into a terminally differentiated cell that is not part of the initial lineage. Many cancer stem cells do not have this versatility, and this is an essential difference between normal and cancer stem cells. In this report, we review findings that support this notion., This project received funding from the European Union’s Seventh Framework Programme for research, technological development, and demonstration under grant agreement no. 315902. GB and ISG were Partners within the Marie Curie Initial Training Network DECIDE (decision making within cells and differentiation entity therapies). Research in the ISG group is partially supported by SAF2015-64420-R MINECO/FEDER, UE, RTI2018-093314-B-I00 MCIU/AEI/FEDER, UE, Junta de Castilla y León (UIC-017, CSI001U16, and CSI234P18), the German Carreras Foundation (DJCLS R13/26; DJCLS 02R-2016), and the German Federal Office for Radiation Protection (BfS)-Germany (FKZ: 3618S32274)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Editorial: Epigenetic reprogramming and cancer development

  • Brown, Geoffrey
  • Vicente-Dueñas, Carolina
  • Sánchez García, Isidro
Editorial on the Research Topic: Epigenetic Reprogramming and Cancer Development., Research in the CV-D group was partially supported by FEDER, Miguel Servet Grant (CP14/00082-AES 2013-2016) from the Instituto de Salud Carlos III (Ministerio de Economía y Competitividad), Fondo de Investigaciones Sanitarias/Instituto de Salud Carlos III (PI17/00167). Research in IS-G group was partially supported by SAF2015-64420-R MINECO/FEDER, UE, RTI2018-093314-B-I00 MCIU/AEI/FEDER, UE, by Junta de Castilla y León (UIC-017, CSI001U16, and CSI234P18), and by the German Carreras Foundation (DJCLS R13/26 and DJCLS 02R/2016). IS-G lab is a member of the EuroSyStem and the DECIDE Network funded by the European Union under the FP7 program. IS-G and CV-D have been supported by the German Federal Office for Radiation Protection (BfS) (FKZ: 3618S32274). GB lab is a member of the DECIDE Network funded by the European Union under the FP7 program., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Lineage decision-making within normal haematopoietic and leukemic stem cells

  • Brown, Geoffrey
  • Sánchez, Lucía
  • Sánchez García, Isidro
This article belongs to the Special Issue Cellular and Molecular Mechanisms of Hematopoiesis., To produce the wide range of blood and immune cell types, haematopoietic stem cells can “choose” directly from the entire spectrum of blood cell fate-options. Affiliation to a single cell lineage can occur at the level of the haematopoietic stem cell and these cells are therefore a mixture of some pluripotent cells and many cells with lineage signatures. Even so, haematopoietic stem cells and their progeny that have chosen a particular fate can still “change their mind” and adopt a different developmental pathway. Many of the leukaemias arise in haematopoietic stem cells with the bulk of the often partially differentiated leukaemia cells belonging to just one cell type. We argue that the reason for this is that an oncogenic insult to the genome “hard wires” leukaemia stem cells, either through development or at some stage, to one cell lineage. Unlike normal haematopoietic stem cells, oncogene-transformed leukaemia stem cells and their progeny are unable to adopt an alternative pathway., This project received funding from the European Union’s Seventh Framework Programme for research, technological development and demonstration under grant agreement no 315902. Research in ISG group is partially supported by SAF2015-64420-R MINECO/FEDER,UE, RTI2018-093314-B-I00 MCIU/AEI/FEDER,UE, by Junta de Castilla y León (UIC-017, CSI001U16, and CSI234P18), by the German Carreras Foundation (DJCLS 02R-2016; DJCLS 07R/2019) and by the German Federal Office for Radiation Protection (BfS)-Germany (FKZ: 3618S32274), and by the Fundacion Unoentrecienmil (CUNINA project)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Inhibition of inflammatory signaling in Pax5 mutant cells mitigates B-cell leukemogenesis

  • Isidro‑Hernández, Marta
  • Mayado, Andrea
  • Casado-García, Ana
  • Martínez‑Cano, Jorge
  • Palmi, Chiara
  • Fazio, Grazia
  • Orfao, Alberto
  • Ribera, Jordi
  • Ribera, Josep-Maria
  • Zamora, Lurdes
  • Raboso-Gallego, Javier
  • Blanco, Óscar
  • Alonso-López, D.
  • Rivas, Javier de las
  • Jiménez, Rafael
  • García Criado, Francisco Javier
  • García-Cenador, Begoña
  • Ramírez‑Orellana, Manuel
  • Cazzaniga, Giovanni
  • Cobaleda, César
  • Vicente-Dueñas, Carolina
  • Sánchez García, Isidro
© The Author(s) 2020., PAX5 is one of the most frequently mutated genes in B-cell acute lymphoblastic leukemia (B-ALL), and children with inherited preleukemic PAX5 mutations are at a higher risk of developing the disease. Abnormal profiles of inflammatory markers have been detected in neonatal blood spot samples of children who later developed B-ALL. However, how inflammatory signals contribute to B-ALL development is unclear. Here, we demonstrate that Pax5 heterozygosis, in the presence of infections, results in the enhanced production of the inflammatory cytokine interleukin-6 (IL-6), which appears to act in an autocrine fashion to promote leukemia growth. Furthermore, in vivo genetic downregulation of IL-6 in these Pax5 heterozygous mice retards B-cell leukemogenesis, and in vivo pharmacologic inhibition of IL-6 with a neutralizing antibody in Pax5 mutant mice with B-ALL clears leukemic cells. Additionally, this novel IL–6 signaling paradigm identified in mice was also substantiated in humans. Altogether, our studies establish aberrant IL6 expression caused by Pax5 loss as a hallmark of Pax5-dependent B-ALL and the IL6 as a therapeutic vulnerability for B-ALL characterized by PAX5 loss., We would also like to thank all members of our groups for useful suggestions and for their critical reading of the manuscript. Research at G.C.’s laboratory was supported by Italian Association for Cancer Research (grant IG-17593 to GC) and Fondazione Cariplo (grant 2018-0339 to CP). Research at CC’s laboratory was partially supported by FEDER, EU, MINECO (SAF2017-83061-R), the “Fundación Ramón Areces,” a Research Contract with the “Fundación Síndrome de Wolf-Hirschhorn o 4p-”, and institutional grants from the “Fundación Ramón Areces” and “Banco de Santander” to the CBMSO. Research in the CVD group is partially supported by FEDER, “Miguel Servet” Grant (CPII19/00024—AES 2017-2020) from the Instituto de Salud Carlos III (Ministerio de Economía y Competitividad), “Fondo de Investigaciones Sanitarias/Instituto de Salud Carlos III” (PI17/00167). Research in the ISG group is partially supported by FEDER and by SAF2015-64420-R MINECO/FEDER, UE, RTI2018-093314-B-I00 MCIU/AEI/FEDER, UE, by Junta de Castilla y León (UIC-017, CSI001U16, and CSI234P18), and by the German Jose Carreras Foundation (DJCLS R13/26; DJCLS 07R/2019). CVD, and ISG have been supported by the German Federal Office for Radiation Protection (BfS)-Germany (FKZ: 3618S32274). M.R.O., and ISG have been supported by the Fundacion Unoentrecienmil (CUNINA project). Research in the A.O. group is partially supported by "Fondo de Investigaciones Sanitarias/Instituto de Salud Carlos III" - FEDER-Ministerio de Economía y Competitividad (PI19/01183). AC-G and M.I.-H. are supported by FSE-Conserjería de Educación de la Junta de Castilla y León 2019 and 2020 (ESF- European Social Fund) fellowship, respectively. J.R.-G. is supported by a scholarship from University of Salamanca co-financed by Banco Santander and ESF.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

An intact gut microbiome protects genetically predisposed mice against leukemia

  • Vicente-Dueñas, Carolina
  • Janssen, Stefan
  • Oldenburg, Marina
  • Auer, Franziska
  • González-Herrero, Inés
  • Casado-García, Ana
  • Isidro‑Hernández, Marta
  • Raboso-Gallego, Javier
  • Westhoff, Philipp
  • Pandyra, Aleksandra A.
  • Hein, Daniel
  • Gössling, Katharina L.
  • Alonso-López, D.
  • Rivas, Javier de las
  • Bhatia, Sanil
  • García-Criado, Francisco Javier
  • García-Cenador, Begoña
  • Weber, Andreas P. M.
  • Köhrer, Karl
  • Hauer, Julia
  • Fischer, Ute
  • Sánchez García, Isidro
  • Borkhardt, Arndt
© 2020 by The American Society of Hematology, The majority of childhood leukemias are precursor B-cell acute lymphoblastic leukemias (pB-ALLs) caused by a combination of prenatal genetic predispositions and oncogenic events occurring after birth. Although genetic predispositions are frequent in children (>1% to 5%), fewer than 1% of genetically predisposed carriers will develop pB-ALL. Although infectious stimuli are believed to play a major role in leukemogenesis, the critical determinants are not well defined. Here, by using murine models of pB-ALL, we show that microbiome disturbances incurred by antibiotic treatment early in life were sufficient to induce leukemia in genetically predisposed mice, even in the absence of infectious stimuli and independent of T cells. By using V4 and full-length 16S ribosomal RNA sequencing of a series of fecal samples, we found that genetic predisposition to pB-ALL (Pax5 heterozygosity or ETV6-RUNX1 fusion) shaped a distinct gut microbiome. Machine learning accurately (96.8%) predicted genetic predisposition using 40 of 3983 amplicon sequence variants as proxies for bacterial species. Transplantation of either wild-type (WT) or Pax5+/– hematopoietic bone marrow cells into WT recipient mice revealed that the microbiome is shaped and determined in a donor genotype–specific manner. Gas chromatography-mass spectrometry (GC-MS) analyses of sera from WT and Pax5+/– mice demonstrated the presence of a genotype-specific distinct metabolomic profile. Taken together, our data indicate that it is a lack of commensal microbiota rather than the presence of specific bacteria that promotes leukemia in genetically predisposed mice. Future large-scale longitudinal studies are required to determine whether targeted microbiome modification in children predisposed to pB-ALL could become a successful prevention strategy., This study and research in the C.V.-D. group were supported by FEDER, “Miguel Servet” Grant (CP14/00082-AES 2013-2016) from the Instituto de Salud Carlos III (Ministerio de Economía y Competitividad), “Fondo de Investigaciones Sanitarias/Instituto de Salud Carlos III” (PI17/00167). J.H. was supported by ERAPer Med “GEPARD”, the German Cancer AID (Translational Oncology Program 70112951), the ERCStg 85222 “PreventALL”, The German Jose Carreras Foundation (DJCLS 02R/2016 and 07R/2019), and the Kinderkrebsstiftung (2016/17). A.B. was supported by the Katharina-Hardt-Stiftung, the German Children’s Cancer Foundation, and the Federal Ministry of Education and Research, Bonn, Germany. The I.S.-G. group was partially supported by SAF2015-64420-R MINECO/FEDER, UE, RTI2018-093314-B-I00 MCIU/AEI/FEDER, UE, and by Junta de Castilla y León (UIC-017, CSI001U16, and CSI234P18). The I.S.-G. laboratory is a member of the EuroSyStem and the DECIDE Network funded by the European Union under the FP7 program. A.B. and I.S.-G. were supported by the German Carreras Foundation (DJCLS R13/26). A.B., U.F., D.H. (FKZ: 3618S32275 and 3618S32274), I.S.-G., and C.V.-D. (FKZ: 3618S32274) were supported by the German Federal Office for Radiation Protection (BfS). Computational support and infrastructure was provided by the “Centre for Information and Media Technology” (ZIM) at the Heinrich-Heine-University of Düsseldorf. U.F. was supported by the German Carreras Foundation (DJCLS 21R/2019) and by the Research Commission of the Medical Faculty of the Heinrich-Heine-University of Düsseldorf (2016/70). D.H. was supported by the Research Commission of the Medical Faculty of the Heinrich-Heine-University of Düsseldorf (2019/03).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

An immune window of opportunity to prevent childhood B cell leukemia

  • Cobaleda, César
  • Vicente-Dueñas, Carolina
  • Sánchez García, Isidro
The prevalence of childhood B cell acute lymphoblastic leukemia (B-ALL) is increasing, particularly in developed countries. There is no clear explanation for this increment, but recent data suggest that, besides genetic predisposition, stress in the immune system (e.g., an infection) might have an important role in B-ALL leukemogenesis. Here, we speculate on how this knowledge might impact B-ALL prevention strategies., Research in C.C.’s laboratory was partially supported by FEDER MINECO (SAF2017-83061-R), the ‘Fundación Ramón Areces’, and a Research Contract with the ‘Fundación Síndrome de Wolf-Hirschhorn o 4p-‘. Institutional grants from the ‘Fundación Ramón Areces’ and ‘Banco de Santander’ to the CBMSO are also acknowledged. The C.C. and C.V-D. labs are members of the EU COST Action LEGEND (CA16223). Research in the C.V-D. group is partially supported by FEDER, ‘Miguel Servet’ Grant (CPII19/00024 - AES 2017-2020) from the Instituto de Salud Carlos III (Ministerio de Economía y Competitividad) and ‘Fondo de Investigaciones Sanitarias/Instituto de Salud Carlos III’ (PI17/00167). Research in the I.S-G. group is partially supported by FEDER and by SAF2015-64420-R MINECO/FEDER, UE, RTI2018-093314-B-I00 MCIU/AEI/FEDER, UE, Junta de Castilla y León (UIC-017, CSI001U16, CSI234P18, and CSI144P20), the German Carreras Foundation (DJCLS 07R/2019), and the Fundacion Unoentrecienmil (CUNINA project). The I.S-G. lab is a member of the EuroSyStem and DECIDE Network funded by the European Union under the FP7 program. C.V-D. and I.S-G. have been supported by the German Federal Office for Radiation Protection (BfS)-Germany (FKZ: 3618S32274).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Infectious triggers and novel therapeutic opportunities in childhood B cell leukaemia

  • Cobaleda, César
  • Vicente-Dueñas, Carolina
  • Sánchez García, Isidro
B cell acute lymphoblastic leukaemia (B-ALL) is the most common form of childhood cancer. Although treatment has advanced remarkably in the past 50 years, it still fails in ~20% of patients. Recent studies revealed that more than 5% of healthy newborns carry preleukaemic clones that originate in utero, but only a small percentage of these carriers will progress to overt B-ALL. The drivers of progression are unclear, but B-ALL incidence seems to be increasing in parallel with the adoption of modern lifestyles. Emerging evidence shows that a major driver for the conversion from the preleukaemic state to the B-ALL state is exposure to immune stressors, such as infection. Here, we discuss our current understanding of the environmental triggers and genetic predispositions that may lead to B-ALL, highlighting lessons from epidemiology, the clinic and animal models, and identifying priority areas for future research., Research at C.C.’s laboratory was partially supported by the European Regional Development Fund (FEDER)/MINECO (SAF2017-83061-R), Fundación Ramón Areces and a research contract with Fundación Síndrome de Wolf-Hirschhorn o 4p-. Institutional grants from Fundación Ramón Areces and Banco de Santander to Centro de Biología Molecular Severo Ochoa are also acknowledged. The C.C. and C.V.-D. laboratories are members of the EU COST Action LEGEND (CA16223). Research in the C.V.-D. group is partially supported by an FEDER Miguel Servet grant (CPII19/00024 — AES 2017-2020) from Instituto de Salud Carlos III (Ministerio de Economía y Competitividad), Fondo de Investigaciones Sanitarias/Instituto de Salud Carlos III (PI17/00167). Research in the I.S.-G. group is partially supported by the FEDER and by MINECO/FEDER (SAF2015-64420-R), MCIU/AEI/FEDER (RTI2018-093314-B-I00), Junta de Castilla y León (UIC-017, CSI001U16, CSI234P18 and CSI144P20), the German Carreras Foundation (DJCLS 07R/2019) and Fundacion Unoentrecienmil (CUNINA project). The I.S.-G. laboratory is a member of EuroSyStem and the DECIDE Network funded by the European Union under the Seventh Framework Programme. C.V.-D. and I.S.-G. have been supported by the German Federal Office for Radiation Protection (BfS) (FKZ: 3618S32274).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Leukemia Stem Cell Drug Discovery

  • Cobaleda, César
  • Sánchez García, Isidro
The relative survival of cancer patients, when considering the tumoral stage at diagnosis, has not changed significantly in the last three decades, in spite of our increasingly detailed knowledge of the molecular alterations occurring in human tumors. In parallel, despite a growing number of clinical trials being conducted, the absolute number of drugs that are effective in humans is declining, and many new drugs move into the market without having enough evidence of their benefit on survival or quality of life. In part, this failure is due to the discordance between the results from preclinical and clinical trial phases, therefore leading to a high percentage of apparently promising lead compounds being abandoned in the transfer to the clinic. This discordance is caused, to a large degree, by the use of inappropriate animal models in the first stages of drug development. In this chapter, we discuss how the development of cancer therapies needs to be redesigned in order to achieve cancer cure, and how this redesign must involve the generation of better animal models, based on the tenets of the cancer stem cell theory, and capable of recapitulating all the aspects of human cancer. The use of such improved models should increase the likelihood of success in drug development, reducing the number of agents that go into trial, and the amount of patients undergoing useless trials., Research at CC’s laboratory was partially supported by FEDER, EU, MINECO (SAF2017-83061-R), the “Fundación Ramón Areces,” a Research Contract with the “Fundación Síndrome de Wolf-Hirschhorn o 4p-,” and institutional grants from the “Fundación Ramón Areces” and “Banco de Santander” to the CBMSO. Research in ISG group is partially supported by FEDER and by SAF2015-64420-R MINECO/FEDER, UE, RTI2018-093314-B-I00 MCIU/AEI/FEDER,UE, by Junta de Castilla y León (UIC-017, CSI001U16, and CSI234P18), by The German Carreras Foundation (DJCLS 02R/2016 and DJCLS 07R_2019), by the German Federal Office for Radiation Protection (BfS)-Germany (FKZ: 3618S32274), and by the Fundacion Unoentrecienmil (CUNINA project). ISG lab is a member of the EuroSyStem and the DECIDE Network funded by the European Union under the FP7 program.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Leukemia Stem Cells: Concept and Implications

  • Sánchez García, Isidro
  • Cobaleda, César
Only 10 years ago, the existence of cancer stem cells (CSCs) was still hotly debated. Even today, when their presence in most tumor types has been clearly demonstrated, all the consequences of their existence are far from being realized neither in the clinic nor, very often, in basic and translational cancer research. The existence of CSCs supposes a true change of paradigm in our understanding of cancer, but it will only have a real impact when we will properly assimilate its implications and apply these insights to both cancer research and cancer treatment. In this primer to the topic of leukemia stem cells (LSCs) our aim is to highlight with broad brushstrokes the most relevant of their properties, how these characteristics led to their identification, and the implications that the existence of LSCs has for the research and fight against leukemia., Research at CC’s laboratory was partially supported by FEDER, EU, MINECO (SAF2017-83061-R), the “Fundación Ramón Areces,” a Research Contract with the “Fundación Síndrome de Wolf-Hirschhorn o 4p-,” and institutional grants from the “Fundación Ramón Areces” and “Banco de Santander” to the CBMSO. Research in ISG group is partially supported by FEDER and by SAF2015-64420-R MINECO/FEDER, UE, RTI2018-093314-B-I00 MCIU/AEI/FEDER,UE, by Junta de Castilla y León (UIC-017, CSI001U16, and CSI234P18), by The German Carreras Foundation (DJCLS 02R/2016 and DJCLS 07R_2019), by the German Federal Office for Radiation Protection (BfS)-Germany (FKZ: 3618S32274), and by the Fundacion Unoentrecienmil (CUNINA project). ISG lab is a member of the EuroSyStem and the DECIDE Network funded by the European Union under the FP7 program.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The Second Oncogenic Hit Determines the Cell Fate of ETV6-RUNX1 Positive Leukemia

  • Rodríguez-Hernández, Guillermo
  • Casado-García, Ana
  • Isidro‑Hernández, Marta
  • Picard, Daniel
  • Raboso-Gallego, Javier
  • Alemán-Arteaga, Silvia
  • Orfao, Alberto
  • Blanco, Óscar
  • Riesco, Susana
  • Prieto-Matos, Pablo
  • García-Criado, Francisco Javier
  • García-Cenador, Begoña
  • Hock, Hanno
  • Enver, Tariq
  • Sánchez García, Isidro
  • Vicente-Dueñas, Carolina
© 2021 Rodríguez-Hernández, Casado-García, Isidro-Hernández, Picard, Raboso-Gallego, Alemán-Arteaga, Orfao, Blanco, Riesco, Prieto-Matos, García Criado, García Cenador, Hock, Enver, Sanchez-Garcia and Vicente-Dueñas., ETV6-RUNX1 is almost exclusively associated with childhood B-cell acute lymphoblastic leukemia (B-ALL), but the consequences of ETV6-RUNX1 expression on cell lineage decisions during B-cell leukemogenesis are completely unknown. Clinically silent ETV6-RUNX1 preleukemic clones are frequently found in neonatal cord blood, but few carriers develop B-ALL as a result of secondary genetic alterations. The understanding of the mechanisms underlying the first transforming steps could greatly advance the development of non-toxic prophylactic interventions. Using genetic lineage tracing, we examined the capacity of ETV6-RUNX1 to instruct a malignant phenotype in the hematopoietic lineage by cell-specific Cre-mediated activation of ETV6-RUNX1 from the endogenous Etv6 gene locus. Here we show that, while ETV6-RUNX1 has the propensity to trigger both T- and B-lymphoid malignancies, it is the second hit that determines tumor cell identity. To instigate leukemia, both oncogenic hits must place early in the development of hematopoietic/precursor cells, not in already committed B-cells. Depending on the nature of the second hit, the resulting B-ALLs presented distinct entities that were clearly separable based on their gene expression profiles. Our findings give a novel mechanistic insight into the early steps of ETV6-RUNX1+ B-ALL development and might have major implications for the potential development of ETV6-RUNX1+ B-ALL prevention strategies., Research in CV-D group has been funded by Instituto de Salud Carlos III through the project “PI17/00167” and by a “Miguel Servet Grant” (CPII19/00024—AES 2017–2020), co-funded by European Regional Development Fund/European Social Fund (“A way to make Europe”/“Investing in your future”). Research in the IS-G group is partially supported by FEDER and SAF2015-64420-R MINECO/FEDER, UE, RTI2018-093314-B-I00 MCIU/AEI/FEDER, UE, and by Junta de Castilla y León (UIC-017, CSI001U16, CSI234P18, and CSI144P20). The IS-G lab is a member of the EuroSyStem and the DECIDE Network funded by the European Union under the FP7 program. CV-D and IS-G have been supported by the German Federal Office for Radiation Protection (BfS)–Germany (FKZ: 3618S32274). IS-G has been supported by the Fundacion Unoentrecienmil (CUNINA project). HH was supported by a Hyundai Hope on Wheels scholar grant. GR-H was supported by FSE-Conserjería de Educación de la Junta de Castilla y León (CSI001-15). AC-G and MI-H are supported by FSE-Conserjería de Educación de la Junta de Castilla y León 2019 and 2020 (ESF—European Social Fund) fellowship, respectively (REF. CSI067-18 and CSI021-19). JR-G was supported by a scholarship from the University of Salamanca, co-financed by Banco Santander and ESF. SA-A was supported by RTI2018-093314-B-I00 MCIU/AEI/FEDER fellowship (PRE2019-088887).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Childhood B-Cell Preleukemia Mouse Modeling

  • Isidro‑Hernández, Marta
  • Alemán-Arteaga, Silvia
  • Casado-García, Ana
  • Ruiz-Corzo, Belén
  • Riesco, Susana
  • Prieto-Matos, Pablo
  • Martínez-Cano, Jorge
  • Sánchez, Lucía
  • Cobaleda, César
  • Sánchez García, Isidro
  • Vicente-Dueñas, Carolina
Leukemia is the most usual childhood cancer, and B-cell acute lymphoblastic leukemia (B-ALL) is its most common presentation. It has been proposed that pediatric leukemogenesis occurs through a “multi-step” or “multi-hit” mechanism that includes both in utero and postnatal steps. Many childhood leukemia-initiating events, such as chromosomal translocations, originate in utero, and studies so far suggest that these “first-hits” occur at a far higher frequency than the incidence of childhood leukemia itself. The reason why only a small percentage of the children born with such preleukemic “hits” will develop full-blown leukemia is still a mystery. In order to better understand childhood leukemia, mouse modeling is essential, but only if the multistage process of leukemia can be recapitulated in the model. Therefore, mouse models naturally reproducing the “multi-step” process of childhood B-ALL will be essential to identify environmental or other factors that are directly linked to increased risk of disease., Research in CV-D group has been funded by Instituto de Salud Carlos III (ISCIII), through a “Miguel Servet Grant” (CPII19/00024-AES 2017–2020); co-funded by the European Union. Research in IS-G group is partially supported by FEDER and by SAF2015-64420-R MINECO/FEDER, UE, RTI2018-093314-B-I00 MCIU/AEI/FEDER, UE, by PID2021-122185OB-I00 MCIU/AEI/FEDER, UE, and by Junta de Castilla y León (UIC-017, CSI001U16, CSI234P18, and CSI144P20). IS-G have been supported by the Fundacion Unoentrecienmil (CUNINA project). CC and IS-G have been supported by the Fundación Científica de la Asociación Española contra el Cáncer (PRYCO211305SANC). Research at CC’s laboratory was partially supported by Ministerio de Ciencia e Innovación/AEI/FEDER (PID2021-122787OB-I00), FEDER MINECO (SAF2017-83061-R), the “Fundación Ramón Areces” and a Research Contract with the “Fundación Síndrome de Wolf-Hirschhorn o 4p-”. Institutional grants from the “Fundación Ramón Areces” and “Banco de Santander” to the CBMSO are also acknowledged. J.M.-C. is the recipient of a UAM FPU fellowship. AC-G (CSI067-18) and MI-H (CSI021-19) are supported by FSE-Conserjería de Educación de la Junta de Castilla y León 2019 and 2020 (ESF—European Social Fund) fellowship, respectively. SA-A is supported by an Ayuda para Contratos predoctorales para la formación de doctores (PRE2019-088887). L.S. is supported by a scholarship from University of Salamanca co-financed by Banco Santander and ESF.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Transient inhibition of the JAK/STAT pathway prevents B-ALL development in genetically predisposed mice

  • Casado-García, Ana
  • Isidro‑Hernández, Marta
  • Oak, Ninad
  • Mayado, Andrea
  • Mann-Ran, Christine
  • Raboso-Gallego, Javier
  • Alemán-Arteaga, Silvia
  • Buhles, Alexandra
  • Sterker, Dario
  • Sánchez, Elena G.
  • Martínez-Cano, Jorge
  • Blanco, Óscar
  • Orfao, Alberto
  • Alonso-López, D.
  • De Las Rivas, Javier
  • Riesco, Susana
  • Prieto-Matos, Pablo
  • González-Murillo, África
  • García-Criado, Francisco Javier
  • García-Cenador, Begoña
  • Radimerski, Thomas
  • Ramírez‑Orellana, Manuel
  • Cobaleda, César
  • Yang, Jun J.
  • Vicente-Dueñas, Carolina
  • Weiss, Andreas
  • Nichols, Kim E.
  • Sánchez García, Isidro
Preventing development of childhood B-cell acute lymphoblastic leukemia (B-ALL), a disease with devastating effects, is a longstanding and unsolved challenge. Heterozygous germline alterations in the PAX5 gene can lead to B-ALL upon accumulation of secondary mutations affecting the JAK/STAT signaling pathway. Preclinical studies have shown that this malignant transformation occurs only under immune stress such as exposure to infectious pathogens. Here we show in Pax5+/− mice that transient, early-life administration of clinically relevant doses of ruxolitinib, a JAK1/2 inhibitor, significantly mitigates the risk of B-ALL following exposure to infection; 1 of 29 animals treated with ruxolitinib developed B-ALL versus 8 of 34 untreated mice. Ruxolitinib treatment preferentially targeted Pax5+/− versus wild-type B-cell progenitors and exerted unique effects on the Pax5+/− B-cell progenitor transcriptional program. These findings provide the first in vivo evidence for a potential strategy to prevent B-ALL development., C. Cobaleda and C. Vicente-Dueñas labs are members of the EU COST Action LEGEND (CA16223). Research in C. Vicente-Dueñas group has been funded by Instituto de Salud Carlos III through the project " PI17/00167 and by a “Miguel Servet Grant” [CPII19/00024 - AES 2017-2020; co-funded by European Regional Development Fund (ERDF)/European Social Fund (ESF) "A way to make Europe"/"Investing in your future"]. J.J. Yang and K.E. Nichols receive funding from the American Lebanese Syrian Associated Charities (ALSAC) and R01CA241452 from the NCI. Research in ISG group is partially supported by FEDER and by SAF2015-64420-R MINECO/FEDER, UE, RTI2018-093314-B-I00 MCIU/AEI/FEDER, UE, 9659122185-122185-4-21 MCIU/AEI/FEDER, UE, by Junta de Castilla y León (UIC-017, CSI001U16, CSI234P18, and CSI144P20). M. Ramírez-Orellana and I. Sánchez-García have been supported by the Fundacion Unoentrecienmil (CUNINA project). C. Cobaleda, M. Ramírez-Orellana, and I. Sánchez-García have been supported by the Fundación Científica de la Asociación Española contra el Cáncer (PRYCO211305SANC). A. Casado-García (CSI067-18) and M. Isidro-Hernández (CSI021-19) are supported by FSE-Conserjería de Educación de la Junta de Castilla y León 2019 and 2020 (ESF, European Social Fund) fellowship, respectively. J. Raboso-Gallego is supported by a scholarship from University of Salamanca co-financed by Banco Santander and ESF. S. Alemán-Arteaga is supported by an Ayuda para Contratos predoctorales para la formación de doctores (PRE2019-088887).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Immune stress suppresses innate immune signaling in preleukemic precursor B-cells to provoke leukemia in predisposed mice

  • Isidro‑Hernández, Marta
  • Casado-García, Ana
  • Oak, Ninad
  • Alemán-Arteaga, Silvia
  • Ruiz-Corzo, Belén
  • Martínez-Cano, Jorge
  • Mayado, Andrea
  • Sánchez, Elena G.
  • Blanco, Óscar
  • Gaspar, Ma Luisa
  • Orfao, Alberto
  • Alonso-López, Diego
  • De Las Rivas, Javier
  • Riesco, Susana
  • Prieto-Matos, Pablo
  • González-Murillo, África
  • Criado, Francisco Javier García
  • García-Cenador, Begoña
  • Ramírez-Orellana, Manuel
  • de Andrés, Belén
  • Vicente-Dueñas, Carolina
  • Cobaleda, César
  • Nichols, Kim E.
  • Sánchez García, Isidro
The initial steps of B-cell acute lymphoblastic leukemia (B-ALL) development usually pass unnoticed in children. Several preclinical studies have shown that exposure to immune stressors triggers the transformation of preleukemic B cells to full-blown B-ALL, but how this takes place is still a longstanding and unsolved challenge. Here we show that dysregulation of innate immunity plays a driving role in the clonal evolution of pre-malignant Pax5 B-cell precursors toward leukemia. Transcriptional profiling reveals that Myd88 is downregulated in immune-stressed pre-malignant B-cell precursors and in leukemic cells. Genetic reduction of Myd88 expression leads to a significant increase in leukemia incidence in Pax5 Myd88 mice through an inflammation-dependent mechanism. Early induction of Myd88-independent Toll-like receptor 3 signaling results in a significant delay of leukemia development in Pax5 mice. Altogether, these findings identify a role for innate immunity dysregulation in leukemia, with important implications for understanding and therapeutic targeting of the preleukemic state in children., Research at C. Cobaleda’s laboratory was partially supported by Ministerio de Ciencia e Innovación/AEI/FEDER (PID2021-122787OBI00), and a Research Contract with the “Fundación Síndrome de WolfHirschhorn o 4p-”. Institutional grants from the “Fundación Ramón Areces” and “Banco de Santander” to the CBMSO are also acknowledged. Research in C. Vicente-Dueñas group has been funded by Instituto de Salud Carlos III through the project “ PI22/00379 and by a “Miguel Servet Grant” [CPII19/00024-AES 2017-2020; co-funded by European Regional Development Fund (ERDF)/European Social Fund (ESF) “A way to make Europe”/“Investing in your future”]. Kim Nichols receives funding from the American Lebanese Syrian Associated Charities (ALSAC) and R01CA241452 from the National Cancer Institute Research in ISG group is partially supported by FEDER and by SAF2015-64420-R MINECO/FEDER, UE; by RTI2018-093314-B-I00 MCIU/AEI/FEDER, UE; by PID2021-122185OB-I00 MCIU/AEI/FEDER, UE, and by Junta de Castilla y León (UIC-017, CSI001U16, CSI234P18, and CSI144P20). Research in BdA group is partially supported by RTI2019- 09114-B-I00 MCIU/AEI/FEDER, UE. M. Ramírez-Orellana and I. Sánchez-García have been supported by the Fundacion Unoentrecienmil (CUNINA project). C. Cobaleda, M. Ramírez-Orellana, and I. Sánchez-García have been supported by the Fundación Científica de la Asociación Española contra el Cáncer (PRYCO211305SANC). A. Casado-García (CSI067-18) and M. Isidro-Hernández (CSI021-19) are supported by FSE-Conserjería de Educación de la Junta de Castilla y León 2019 and 2020 (ESF, European Social Fund) fellowship, respectively. S. Alemán-Arteaga is supported by an Ayuda para Contratos predoctorales para la formación de doctores (PRE2019- 088887). J. Martínez-Cano is supported by a predoctoral fellowship FPI-UAM 2019. We also thank the Hartwell Center and Dr. Ti-Cheng Chang from the Center for Bioinformatics at SJCRH for their support of the whole genome sequencing and bioinformatic pipelines., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Lessons from mouse models in the impact of risk factors on the genesis of childhood B-cell leukemia

  • Casado-García, Ana
  • Isidro‑Hernández, Marta
  • Alemán-Arteaga, Silvia
  • Ruiz-Corzo, Belén
  • Riesco, Susana
  • Prieto-Matos, Pablo
  • Sánchez, Lucía
  • Sánchez García, Isidro
  • Vicente-Dueñas, Carolina
B-cell acute lymphoblastic leukemia (B-ALL) stands as the primary contributor to childhood cancer-related mortality on a global scale. The development of the most conventional forms of this disease has been proposed to be conducted by two different steps influenced by different types of risk factors. The first step is led by a genetic insult that is presumably acquired before birth that transforms a healthy cell into a preleukemic one, which is maintained untransformed until the second step takes place. This necessary next step to leukemia development will be triggered by different risk factors to which children are exposed after birth. Murine models that recap the stepwise progression of B-ALL have been instrumental in identifying environmental and genetic factors that contribute to disease risk. Recent evidence from these models has demonstrated that specific environmental risk factors, such as common infections or gut microbiome dysbiosis, induce immune stress, driving the transformation of preleukemic cells, and harboring genetic alterations, into fully transformed leukemic cells. Such models serve as valuable tools for investigating the mechanisms underlying preleukemic events and can aid in the development of preventive approaches for leukemia in child. Here, we discuss the existing knowledge, learned from mouse models, of the impact of genetic and environmental risk factors on childhood B-ALL evolution and how B-ALL prevention could be reached by interfering with preleukemic cells., Research in CV-D group has been funded by Instituto de Salud Carlos III (ISCIII) through the project PI22/00379 and co-funded by the European Union (European Regional Development Fund (ERDF)/European Social Fund (ESF)). Research in IS-G group is partially supported by FEDER and by SAF2015-64420-R MINECO/FEDER, UE; by RTI2018-093314-B-I00 MCIU/AEI/FEDER, UE; by PID2021-122185OB-I00 MCIU/AEI/FEDER, UE, and by Junta de Castilla y León (UIC-017, CSI001U16, CSI234P18, and CSI144P20), by the Fundacion Unoentrecienmil (CUNINA project), and by the Fundación Científica de la Asociación Española contra el Cáncer (PRYCO211305SANC). AC-G (CSI067-18), MI-H (CSI021-19) and BR-C are supported by FSE-Conserjería de Educación de la Junta de Castilla y León 2019, 2020, and 2022 (ESF, European Social Fund) fellowship, respectively. SA-A is supported by an Ayuda para Contratos predoctorales para la formación de doctores (PRE2019-088887). LS is supported by a scholarship from the University of Salamanca co-financed by Banco Santander and ESF., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Proof-of-principle: targeted childhood leukemia prevention

  • Cobaleda, César
  • Ramírez-Orellana, Manuel
  • Vicente-Dueñas, Carolina
  • Weiss, Andreas
  • Nichols, Kim E.
  • Sánchez-García, Isidro
Cancer is the most common cause of disease-related childhood mortality in developed countries, with B-cell acute lymphoblastic leukemia (B-ALL) representing the most frequent. A salient characteristic underlying some cases of childhood B-ALL is the presence of congenital mutations (either inherited or de novo) that are compatible with normal lymphocyte development, but lead to the appearance of a silent population of preleukemic cells that acquire additional genetic mutations and ultimately progress to full-blown B-ALL. The precise mechanisms underlying malignant transformation have been difficult to ascertain due to their development in otherwise healthy-appearing children. Notably, several decades ago, delayed exposure to common infections was postulated as a triggering factor leading to the appearance of the secondary genetic lesions required for B-ALL to develop [1]., Research at C. Cobaleda’s laboratory was partially supported by Ministerio de Ciencia e Innovación/AEI/FEDER (PID2021-122787OB-I00), and a Research Contract with the “Fundación Síndrome de Wolf-Hirschhorn o 4p-”. Institutional grants from the “Fundación Ramón Areces” and “Banco de Santander” to the CBMSO are also acknowledged. Research in C. Vicente-Dueñas group has been funded by Instituto de Salud Carlos III through the project “PI22/00379 and by a “Miguel Servet Grant” [CPII19/00024 - AES 2017-2020; co-funded by European Regional Development Fund (ERDF)/European Social Fund (ESF) “A way to make Europe”/”Investing in your future”]. Kim Nichols receives funding from the American Lebanese Syrian Associated Charities (ALSAC) and R01CA241452 from the National Cancer Institute Research in ISG group is partially supported by FEDER and by RTI2018-093314-B-I00 MCIU/AEI/FEDER, UE; by PID2021-122185OB-I00 MCIU/AEI/FEDER, UE, and by Junta de Castilla y León (UIC-017, and CSI144P20). M. Ramírez-Orellana and I. Sánchez-García have been supported by the Fundacion Unoentrecienmil (CUNINA project). C. Cobaleda, M. Ramírez-Orellana, and I. Sánchez-García have been supported by the Fundación Científica de la Asociación Española contra el Cáncer (PRYCO211305SANC).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Insights into the Molecular Mechanisms of Genetic Predisposition to Hematopoietic Malignancies: The Importance of Gene–Environment Interactions

  • Cobaleda, César
  • Godley, Lucy A.
  • Nichols, Kim E.
  • Marcin W. Wlodarski
  • Sánchez García, Isidro
The recognition of host genetic factors underlying susceptibility to hematopoietic malignancies has increased greatly over the last decade. Historically, germline predisposition was thought to primarily affect the young. However, emerging data indicate that hematopoietic malignancies that develop in people of all ages across the human lifespan can derive from germline predisposing conditions and are not exclusively observed in younger individuals. The age at which hematopoietic malignancies manifest appears to correlate with distinct underlying biological pathways. Progression from having a deleterious germline variant to being diagnosed with overt malignancy involves complex, multistep gene–environment interactions with key external triggers, such as infection and inflammatory stimuli, driving clonal progression. Understanding the mechanisms by which predisposed clones transform under specific pressures may reveal strategies to better treat and even prevent hematopoietic malignancies from occurring. Recent unbiased genome-wide sequencing studies of children and adults with hematopoietic malignancies have revealed novel genes in which disease-causing variants are of germline origin. This paradigm shift is spearheaded by findings in myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) as well as acute lymphoblastic leukemia, but it also encompasses other cancer types. Although not without challenges, the field of genetic cancer predisposition is advancing quickly, and a better understanding of the genetic basis of hematopoietic malignancies risk affects therapeutic decisions as well as genetic counseling and testing of at-risk family members., Research at C. Cobaleda's laboratory was partially supported by Ministerio de Ciencia e Innovación/AEI/FEDER (PID2021–122787OB-I00) and a Research Contract with the “Fundación Síndrome de Wolf-Hirschhorn o 4p-.” Institutional grants from the “Fundación Ramón Areces” and “Banco de Santander” to the CBMSO are also acknowledged. L.A. Godley receives funding from NIH/NCI U24CA258118, Edward P. Evans Foundation, NIH/HLHBI via Oregon Health & Science University R01HL155426, Leukemia & Lymphoma Society, NIH/NCI U01CA257666, and RUNX1 Research Program. K. Nichols receives funding from the American Lebanese Syrian Associated Charities (ALSAC), R01CA241452 from the NCI, R21AI113490 from the National Institute of Allergy and Infectious Diseases, Histiocytosis Association, and Cures within Reach. M.W. Wlodarski receives funding from ALSAC, Edward P. Evans Foundation, and The Vera and Joseph Dresner Foundation. Research in ISG group is partially supported by FEDER and by SAF2015–64420-R MINECO/FEDER, UE; by RTI2018–093314-B-I00 MCIU/AEI/FEDER, UE; by PID2021–122185OB-I00 MCIU/AEI/FEDER, UE; by Junta de Castilla y León (UIC-017, CSI001U16, CSI234P18, CSI144P20, and CSI016P23); and by the Fundacion Unoentrecienmil (CUNINA project). C. Cobaleda and I. Sánchez-García have been supported by the Fundación Científica de la Asociación Española contra el Cáncer (PRYCO211305SANC)., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Inhibition of inflammatory signaling in Pax5 mutant cells mitigates B-cell leukemogenesis

  • Isidro-Hernández, Marta
  • Mayado, Andrea
  • Casado-García, Ana
  • Martínez-Cano, Jorge
  • Palmi, Chiara
  • Fazio, Grazia
  • Orfao, Alberto|||0000-0002-0007-7230
  • Ribera Salas, Jordi|||0000-0003-4796-6470
  • Ribera, Jose-Maria|||0000-0003-1042-6024
  • Zamora, Lurdes|||0000-0003-1713-7110
  • Raboso-Gallego, Javier
  • Blanco, Óscar
  • Alonso-López, Diego
  • De Las Rivas, Javier
  • Jiménez, Rafael|||0000-0003-4103-8219
  • García Criado, Francisco Javier
  • García Cenador, María Begoña
  • Ramírez, Manuel|||0000-0003-0332-6973
  • Cazzaniga, Giovanni|||0000-0003-2955-4528
  • Cobaleda, Cesar|||0000-0003-3807-9204
  • Vicente-Dueñas, Carolina
  • Sánchez García, Isidro
PAX5 is one of the most frequently mutated genes in B-cell acute lymphoblastic leukemia (B-ALL), and children with inherited preleukemic PAX5 mutations are at a higher risk of developing the disease. Abnormal profiles of inflammatory markers have been detected in neonatal blood spot samples of children who later developed B-ALL. However, how inflammatory signals contribute to B-ALL development is unclear. Here, we demonstrate that Pax5 heterozygosis, in the presence of infections, results in the enhanced production of the inflammatory cytokine interleukin-6 (IL-6), which appears to act in an autocrine fashion to promote leukemia growth. Furthermore, in vivo genetic downregulation of IL-6 in these Pax5 heterozygous mice retards B-cell leukemogenesis, and in vivo pharmacologic inhibition of IL-6 with a neutralizing antibody in Pax5 mutant mice with B-ALL clears leukemic cells. Additionally, this novel IL-6 signaling paradigm identified in mice was also substantiated in humans. Altogether, our studies establish aberrant IL6 expression caused by Pax5 loss as a hallmark of Pax5-dependent B-ALL and the IL6 as a therapeutic vulnerability for B-ALL characterized by PAX5 loss.